AHA Wrap-Up: Studies Emphasize Improved Outcomes, Cost Effectiveness
Executive Summary
Cardiovascular investigators are now asking new questions, including how can treatment be targeted to those most likely to benefit, and when does aggressive treatment become too much? At the 2006 American Heart Association (AHA) meeting, these questions were at the top of everyone's list, and several highly anticipated studies attempted to provide some answers.
You may also be interested in...
The American Heart Association's scientific sessions in November 2007 presented new clinical data on drug-eluting stents, cardiac resynchronization, treatments for acute coronary syndrome, and better ways of diagnosing and treating myocardial infarction.
The American Heart Association's scientific sessions in November 2007 presented new clinical data on drug-eluting stents, cardiac resynchronization, treatments for acute coronary syndrome, and better ways of diagnosing and treating myocardial infarction.
Guidant emerged as one of the important device companies, all but creating the interventional cardiology business and playing a major role in the evolution of cardiac rhythm management. One person stood behind all of these accomplishments and guided Guidant virtually to its end: Ron Dollens, who retired as CEO last year just before the sale of the company to Boston Scientific was made final. Dollens talks about his career at Eli Lilly and Guidant and about his-and Guidant's-final days.
Existing Subscriber?
Sign in to continue reading.
Need a specific report?
1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests: